Eli Lilly reaches cooperation with RNA editing to treat liver and central nervous system diseases

On September 8, 2021, ProQR Therapeutics announced that it has reached a global licensing and research cooperation agreement with Eli Lilly and Company

This is after Roche and Shape Therapeutics reached a research and development cooperation of up to US$3 billion at the end of August, RNA editors once again won the favor of large pharmaceutical companies

ProQR's proprietary Axiomer platform technology can edit single nucleotides in RNA in a highly targeted and specific manner

More than 20,000 G to A mutations are known to cause human diseases, and these mutations can be reversed using this new technology

▲RNA editing induced by EONs (Image source: ProQR company official website)

According to the terms of the agreement, ProQR will receive 50 million U.

Reference materials:

[1] ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly.

(The original text has been deleted)